On November 28th, OBIO held our 2018 Annual General Meeting at the offices of Norton Rose Fulbright. The exciting event featured Nik Nanos, our keynote speaker whose presentation Global Disruption: How to Make Decisions in an Age When Truth and Data are No Longer Enough to Persuade scanned recent global political experiences and explained the outsized influence of the margins, both on electoral outcomes as well as the impact for your company.
you are considering hiring a new graduate or intern this coming January, it is a good idea to get started now. OBIO H2BB is constantly sourcing new early career talent from top business and innovation programs and is filling roles now.
2019 Call for Applications - NOW OPEN. OBIO CAAP® is a unique, industry-led initiative that provides selected high-potential Ontario health science companies with mentoring, strategic guidance and access to an expansive network of health science industry experts and investors to enhance the ability of OBIO CAAP companies to secure financing.
OBIO is proud to announce a national call for applications from health science companies, seeking Series A and beyond investments, to present at the 2019 Niagara Investment Summit, February 20-22, 2019.
The Ontario Bioscience Innovation Organization (OBIO®) is honoured to announce the conclusion of the successful Canadian Health Investment Showcase which took place in New York, NY, on November 5 and 6, 2018.
OBIO is proud to announce its 2018 Capital Access Advisory Program (CAAP®) and the 11 high-potential health companies in this year’s cohort. Now in its sixth year, this year’s OBIO CAAP companies will work with OBIO and a vast network of expert advisors over the next year to achieve key goals and objectives which will position them for successful financing.
The Ontario Bioscience Innovation Organization (OBIO®) released its latest report, ‘Use It or Lose It: Industry Solutions to Ontario’s Commercialization Gap’, with recommendations from health science company executives on how to create the conditions for the growth of Ontario’s health science industry.
OBIO and Blakes hosted OBIO's third annual pre-RESI networking event, connecting high potential companies with global investors. Over 100 international investors, local investors and strategics, as well as executives from high potential Ontario health science companies
OBIO - in partnership with Accel-Rx - hosted the Niagara Health Science Emerging Company Forum, which brought together CEOs and senior executives from high potential Canadian health science companies with senior leadership from American investors and strategics.
On October 24th, OBIO hosted Health Economics Day workshop in partnership with St. Michael’s Hospital.
The workshop took place in the auditorium at the Li Ka Shing Knowledge Institute and featured four sessions: a moderated panel discussion with four panellists, followed by three presentations by three health economics experts.
Recently, the Minister of Innovation, Science and Economic Development launched a cross country tour to introduce the nine supercluster proposals that have been shortlisted by the federal government for the Innovation Superclusters Initiative.
Grant Burns, OBIO's Public Affairs and Communications Manager, has listed the 9 proposals and provided commentary and analysis on how they relate to the health technology sector.
Bridging the Talent Gap reports on the unique value of OBIO’s Health to Business Bridge (H2BB) business internship program. This report describes how H2BB addresses the challenge of pulling top talent into Ontario’s health science industry to address the talent gap identified by 96% of Ontario’s health science company CEOs.
The “Tackling the Anchor Company Challenge Summit”, assembled industry, academic, government and investment leaders committed to working together to create a mandate of action for anchoring health science companies in Ontario.
In 2017, the Ontario Bioscience Innovation Organization convened a working group (‘OBIO Tax Policy Working Group’, OTPWG) of health science industry leaders and tax experts from academia and the private sector to examine Canada’s tax incentives and their effectiveness in stimulating growth in the health science industry.
"The Ontario Bioscience Innovation Organization (OBIO) strongly believes that the supply chain of the future must incorporate a formal approach to creating pathways for the adoption and procurement of innovation, to benefit the people of Ontario from both a health and economic perspective."
2016 has already been a productive year for OBIO as we push forward on our advocacy efforts, expand our Health Science networks and partnerships and continue to provide access to capital for Ontario Health Science companies in order for them to reach the next level.
Over the past several months, OBESTTM has engaged >200 senior representatives from major stakeholder groups across Ontario’s life-sciences sector. The 6-month strategic planning process has resulted in defined priorities and a plan for robust growth and commercial viability of the province’s bioscience industry.
Ontario's life sciences companies continue to be challenged by the slow global economic recovery. Restrictions in the availability of capital continue to constrain this sector's ability to ensure Ontario's 'human capital' provides its greatest return on our societal investment.
The Consulate General of Canada in Boston is accepting applications for the 2019 Oncology Partnering Initiative, looking for Canadian companies that are developing innovative therapeutics, diagnostics, or research tools addressing needs of companies, researchers or healthcare systems in the oncology space
Cyclica announced the launch of MatchMaker™, a novel deep learning engine which combines molecular biophysics and deep learning to predict binding of new drug molecules to all proteins with high accuracy and high throughput, moving beyond the reliance on molecular docking.
Mobio Interactive's first scientific paper, an active randomised controlled trial, demonstrated that their mindfulness meditation app may provide immediate effects on mood and stress while also providing long-term benefits for attentional control compared to placebo.
Supported by Ontario Genomics, the Genomic Applications Partnership Program (GAPP) funds downstream research and development projects that address real world opportunities and challenges defined by “Receptor” organizations such as industry, government, or not-for-profit entities.